The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.
September 22nd 2023
Circulating tumor DNA status at the time of postoperative minimal residual disease is a prognostic factor of recurrence for patients with radically resected stage II to IV colorectal cancer
25th Annual International Lung Cancer Congress®
Register Now!
BURST CME™: Utilizing Pathology Reports to Inform Treatment Plans Across GI Cancers
View More
Bridging the Care Gap in Anemia in CKD: A Comprehensive Guide to Enhancing Patient Care
Register Now!
20th Annual Meeting of the International Society of Gastrointestinal Oncology®
Register Now!
2022 BURST Year in Review™: Reflecting on Recent Evidence for Testing in Patients with GI Cancers
View More
2nd Annual International Congress on Pediatric Oncology
View More
2022 BURST Year in Review™: How Has Recent Evidence in Testing Elevated Outcomes in Patients with Lung Cancers
View More
Community Practice Connections™: 23rd Annual International Lung Cancer Congress®
View More
Medical Crossfire®: Multidisciplinary Strategies to Leverage Clinical Advances on Immune-Based Therapies for Patients with Hepatocellular Carcinoma
View More
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
View More
Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®
View More
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
Register Now!
PER's Breast Cancer Symposia in San Antonio
Register Now!
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Register Now!
Virtual Tumor Board®: Optimizing HER2 Testing Strategies for Clinical Decision Making in GI Malignancies
View More
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
View More
BURST CME™: Addressing Current Standards and Unmet Needs in Patients with Metastatic Breast Cancer
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
View More
20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
9th Annual School of Gastrointestinal Oncology® (SOGO®)
Register Now!
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Register Now!
New Targets, New Treatments, and New Combinations for the Management of Advanced Prostate Cancer
View More
Show Me the Data! Navigating FGFR, FGFR Resistance, Immunotherapy, and a World of Clinical Trials in Cholangiocarcinoma Treatment
View More
BURST CME™: What Is the Real Risk in Lower-Risk MDS?
View More
BURST CME™: How Does Transfusion Burden Impact Real-World Outcomes in MDS?
View More
BURST CME™: Understanding Transfusion Dependence in Lower-Risk MDS
View More
How We Do It™: Integrating Gene Fusion Testing in Oncology Clinics for Patients with NSCLC
View More
Postoperative ctDNA Provides Prognostic Value for DFS Outcomes in CRC
Circulating tumor DNA status at the time of postoperative minimal residual disease assessment was found to be a prognostic factor for disease-free survival in patients with radically resected stage II to IV colorectal cancer.
HER2 Amplification Shows Prognostic Capabilities in mCRC
August 22nd 2023HER2 amplification appears to be prognostic in patients with RAS wild-type metastatic colorectal cancer but may not be predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.
Avelumab Increases PFS Rates in dMMR/MSI Metastatic CRC
Patients with mismatch repair–deficient and/or microsatellite instability metastatic colorectal cancer experienced a progression-free survival benefit with longer disease control following treatment with avelumab compared with standard second-line chemotherapy.
BDC-1001 Monotherapy Under Further Evaluation in Phase 2 Trial in HER2+ Cancers
The first patients have been dosed in the phase 2 portion of a phase 1/2 trial evaluating BDC-1001 monotherapy in patients with HER2-positive colorectal cancer, endometrial cancer, and gastroesophageal cancer.
Dr Bloomer on the Rationale for the ColoCare Study in Newly Diagnosed CRC
August 4th 2023Amanda Bloomer, PhD, discusses the rationale for launching the ColoCare study, an investigation into the health-related quality of life outcomes of younger vs older adult patients with newly diagnosed colorectal cancer.
Time to Treatment Initiation Affected by Demographics, Socioeconomics in Solid Tumors
Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of TTI, according to findings from a retrospective cohort study published in JCO Oncology Practice.
The FDA has approved trifluridine and tipiracil (Lonsurf) plus bevacizumab (Avastin) for patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; a VEGF inhibitor; and an EGFR inhibitor, if they have RAS wild-type disease.
ERASur Study Evaluates Total Ablative Therapy Plus Systemic Treatment in mCRC
August 1st 2023The safety and efficacy of adding total ablative therapy of all disease sites to standard systemic treatment is being investigated in patients with limited metastatic colorectal cancer as part of the ongoing phase 3 ERASur study.
Social Determinants of Health Correlate With Lower CRC Screening Rates
Isabelle Franklin discusses the effects of social determinants of health on rates of colorectal cancer screening, expands on how these social determinants of health could affect a patient’s likelihood of adhering to screening guidelines, and highlights ways to potentially address these barriers to screening.
Dr Desai on the Evolution of Divarasib in KRAS G12C-mutated CRC
July 19th 2023Jayesh Desai, MBBS, FRACP, discusses the evolution of divarasib, highlighting the rationale for combining the KRAS G12C inhibitor with cetuximab in patients with advanced colorectal cancer harboring KRAS G12C mutations in a phase 1b study.
Examining the Promise of Multicancer Early Detection Tests: Takeaways From the ECLIPSE Trial
July 19th 2023In this sixth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss important takeaways from the ECLIPSE study (NCT04136002), which evaluated a cell-free DNA blood-based test for colorectal cancer in an average-risk population.
IMX-110 Plus Tislelizumab Leads to Tumor Shrinkage in Heavily Pretreated mCRC
Treatment with the combination of the tissue-specific therapeutic IMX-110 and the anti–PD-1 antibody tislelizumab led to tumor shrinkage in heavily pretreated patients with metastatic colorectal cancer.
DKN-01 Plus Bevacizumab/Chemotherapy Advances to Part B in DeFianCe Trial in Advanced CRC
July 13th 2023Leap Therapeutics has launched the randomized, controlled part B of the phase 2 DeFianCe trial, which will evaluate DKN-01 in combination with bevacizumab and chemotherapy as second-line therapy in patients with advanced colorectal cancer.
Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC
The combination of botensilimab and balstilimab elicited durable responses and provided overall survival benefits in patients with microsatellite stable metastatic colorectal cancer that is resistant to chemotherapy and/or immunotherapy.
TAS-102/Bevacizumab Prolongs OS, PFS in Patients With mCRC and Maintained ECOG PS of 0 or 1
July 5th 2023Julien Taieb, MD, discusses the importance of combining fluoropyrimidines with bevacizumab, key findings from the SUNLIGHT trial and the post-hoc analysis, and how these results may shake up the colorectal cancer treatment paradigm.
Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy
Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.